Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nepafenac 0.3% for Prevention and Treatment of Ocular Inflammation and Pain After Cataract Surgery
NCT01109173Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Jun 2010
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nepafenac in ocular inflammation, sponsored by Alcon Inc.. Started Jun 2010; status: completed.
02
Drugs
nepafenac
03
Conditions
ocular inflammation
Beyond the preview
Go deeper on NCT01109173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01109173.